HomeNewsIndustry ReportsDanish Biotech: a Rapid Rise

Danish Biotech: a Rapid Rise

  • February 25, 2022
  • Posted by: EBAN Team
  • Category: Industry Reports, KNOWLEDGE CENTER, Resources, Resources Members Area, Resources-Featured
No Comments

Dealroom.co present Danish Biotech: a Rapid Rise

Covid provided a big publicity opportunity for biotech. Investors of all kinds started taking interest in the companies that had the power to shorten the pandemic, and save millions of lives, through things like vaccine development and rapid variant analysis. For Dansk Biotech’s spring summit, we dived into the rich emerging biotech ecosystem in Denmark, among the fastest-growing in the world.

Download the Report



Are you an emerging Organisation?
We are Here To support You

Have additional questions?

Feel free to contact us under community@eban.org, and we will be more than happy to answer all of your questions.

Regular Price for Angel Networks
1.500€ per year
Price for Emerging Networks
1.000€ per year*
*Networks with less than 200 members or less than 10M invested per year
Regular Price for Angel Federations
2.500€ per year
Price for Emerging Federations
1.500€ per year*
*Federations with less than 200 affiliated angels or less than 3 BANs, VCs, or syndicates be part of their network
Regular Price for Early Stage Funds
2.500€ per year
Price for Emerging Early Stage Funds
1.500€ per year*
*Early Stage Funds with less than 20M AUM
Regular Price for Funding Platforms
2.500€ per year
Price for Emerging Funding Platforms
1.500€ per year*
*Platforms with less than 20M Euros of transactions made